4//SEC Filing
Stueland Katherine 4
Accession 0001689575-25-000017
CIK 0001818331other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 5:18 PM ET
Size
27.7 KB
Accession
0001689575-25-000017
Insider Transaction Report
Form 4
Stueland Katherine
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Class A Common Stock
2025-12-16+18,750→ 25,094 total - Sale
Class A Common Stock
2025-12-16$138.93/sh−369$51,265→ 24,725 total - Sale
Class A Common Stock
2025-12-16$140.08/sh−1,031$144,425→ 23,694 total - Sale
Class A Common Stock
2025-12-16$141.20/sh−2,679$378,287→ 21,015 total - Sale
Class A Common Stock
2025-12-16$142.12/sh−604$85,840→ 20,411 total - Sale
Class A Common Stock
2025-12-16$144.27/sh−940$135,617→ 19,471 total - Sale
Class A Common Stock
2025-12-16$145.36/sh−1,628$236,640→ 17,843 total - Sale
Class A Common Stock
2025-12-16$146.93/sh−1,970$289,449→ 15,873 total - Sale
Class A Common Stock
2025-12-16$148.55/sh−932$138,448→ 14,941 total - Sale
Class A Common Stock
2025-12-16$149.20/sh−274$40,880→ 14,667 total - Sale
Class A Common Stock
2025-12-16$150.75/sh−74$11,156→ 14,593 total - Sale
Class A Common Stock
2025-12-16$140.95/sh−356$50,178→ 14,237 total - Exercise/Conversion
Restricted Stock Unit
2025-12-16−18,750→ 93,750 total→ Class A Common Stock (18,750 underlying)
Footnotes (13)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.85 to $148.76, inclusive.
- [F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.01 to $149.32, inclusive.
- [F12]Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 14,237 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned RSUs representing contingent rights to receive up to an aggregate of 415,368 shares of Class A Common Stock and options to purchase up to an aggregate of 107,610 shares of Class A Common Stock, which RSUs and options vest according to their respective terms.
- [F13]6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on March 16, 2023. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.65 to $139.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 through 11.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.70 to $140.465, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.72 to $141.68, inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.76 to $142.41, inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.75 to $144.74, inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.80 to $145.55, inclusive.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.605 to $147.51, inclusive.
Documents
Issuer
GeneDx Holdings Corp.
CIK 0001818331
Entity typeother
Related Parties
1- filerCIK 0001689575
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 5:18 PM ET
- Size
- 27.7 KB